Designing cost-effective biopharmaceutical facilities using mixed-integer optimization

Biotechnology Progress

Volumn 29, Issue 6, 2013, Pages 1472-1483

  Liu, Songsong ^a   Simaria, Ana S ^a   Farid, Suzanne S ^a   Papageorgiou, Lazaros G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody titers; Biopharmaceutical facility design; Chromatography; Mixed integer non linear programming; Monoclonal antibody purification

Indexed keywords

ANTIBODY TITERS; CHROMATOGRAPHY COLUMNS; DECISION SUPPORT TOOLS; FACILITY DESIGNS; MIXED INTEGER OPTIMIZATION; MIXED-INTEGER NONLINEAR PROGRAMMING; MONOCLONAL ANTIBODIES (MAB); MONOCLONAL ANTIBODY PURIFICATION;

CHROMATOGRAPHY; COST EFFECTIVENESS; DECISION SUPPORT SYSTEMS; DESIGN; INTEGER PROGRAMMING; MONOCLONAL ANTIBODIES; NONLINEAR PROGRAMMING; OPTIMIZATION; PURIFICATION; TOOLS;

COLUMN CHROMATOGRAPHY;

MONOCLONAL ANTIBODY;

ANTIBODY TITERS; ARTICLE; BIOPHARMACEUTICAL FACILITY DESIGN; CHEMISTRY; CHROMATOGRAPHY; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MIXED INTEGER NON-LINEAR PROGRAMMING; MONOCLONAL ANTIBODY PURIFICATION; THEORETICAL MODEL;

ANTIBODY TITERS; BIOPHARMACEUTICAL FACILITY DESIGN; CHROMATOGRAPHY; MIXED INTEGER NON-LINEAR PROGRAMMING; MONOCLONAL ANTIBODY PURIFICATION;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY; COST-BENEFIT ANALYSIS; HUMANS; MODELS, THEORETICAL;

EID: 84890168010     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1795     Document Type: Article

References (29)

1. Low D, O'Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:48-63.
2. Langer E. Downstream factors that will continue to constrain manufacturing through 2013. BioProcessing J. 2009;8:22-26.
3. Pujar NS, Low D, O'Leary R. Antibody purification: drivers of change. In: Gottschalk U, editor. Process Scale Purification of Antibodies. New Jersey: Wiley; 2009:407-426.
4. Farid SS. Process economic drivers in industrial monoclonal antibody manufacture. In: Gottschalk U, editor. Process Scale Purification of Antibodies. New Jersey: Wiley; 2009:239-261.
5. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Prog. 2007;23:995-1008.
6. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs. 2009;1:443-452.
7. Farid SS, Washbrook J, Titchener-Hooker NJ. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog. 2005;21:486-497.
8. Farid SS, Washbrook J, Titchener-Hooker NJ. Modelling biopharmaceutical manufacture: design and implementation of SimBiopharma. Comput Chem Eng. 2007;31:1141-1158.
9. Lim AC, Zhou Y, Washbrook J, Sinclair A, Fish B, Francis R, Titchener-Hooker NJ, Farid SS. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol Prog. 2005;21:1231-1242.
10. Lim AC, Washbrook J, Titchener-Hooker NJ, Farid SS. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol Bioeng. 2006;93:687-697.
11. Chhatre S, Jones C, Francis R, O'Donovan K, Titchener-Hooker NJ, Newcombe A Keshavarz-Moore E. The integrated simulation and assessment of the impacts of process change in biotherapeutic antibody production. Biotechnol Prog. 2006;23:1612-1620.
12. Joseph JR, Sinclair A, Tichener-Hooker NJ, Zhou Y. A framework for assessing the solutions in chromatographic process design and operation for large-scale manufacture. J Chem Technol Biotechnol. 2006;81:1009-1020.
13. Chhatre S, Thillaivinayagalingam P, Francis R, Titchener-Hooker NJ, Newcombe A Keshavarz-Moore E. Decision-support software for the industrial-scale chromatographic purification of antibodies. Biotechnol Prog. 2007;23:888-894.
14. Stonier A, Simaria AS, Smith M, Farid SS. Decisional tool to assess current and future process robustness in an antibody purification facility. Biotechnol Prog. 2012;28:1019-1028.
15. Papageorgiou LG, Rotstein GE, Shah N. Strategic supply chain optimization for the pharmaceutical industries. Ind Eng Chem Res. 2001;40:275-286.
16. Levis AA, Papageorgiou LG. A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry. Comput Chem Eng. 2004;28:707-725.
17. Lakhdar K, Zhou Y, Savery J, Titchener-Hooker N J, Papageorgiou LG. Medium term planning of biopharmaceutical manufacture using mathematical programming. Biotechnol Prog. 2005;21:1478-1489.
18. Lakhdar K, Savery J, Papageorgiou LG, Farid SS. Multiobjective long-term planning of biopharmaceutical manufacturing facilities. Biotechnol Prog. 2007;23:1383-1393.
19. Vasquez-Alvarez E, Pinto JM. Efficient MILP formulations for the optimal synthesis of chromatographic protein purification processes. J Biotechnol. 2004;110:295-311.
20. Simeonidis E, Pinto JM, Lienqueo ME, Tsoka S, Papageorgiou LG. MINLP models for the synthesis of optimal peptide tags and downstream protein processing. Biotechnol Prog. 2005;21:875-884.
21. Natali JM, Pinto JM, Papageorgiou LG. Efficient MILP formulations for the simultaneous optimal peptide tag design and downstream processing synthesis. AIChE J. 2009;55:2303-2317.
22. Vasquez-Alvarez E, Pinto JM. A mixed integer linear programing model for the optimal synthesis of protein purification processes with product loss. Chem Biochem Eng Q. 2003;17:77-84.
23. Polykarpou EM, Dalby PA, Papageorgiou LG. Optimal synthesis of chromatographic trains for downstream protein processing. Biotechnol Prog. 2011;27:1653-1660.
24. Polykarpou EM, Dalby PA, Papageorgiou LG. A novel efficient optimisation system for purification process synthesis. Biochem Eng J. 2012;67:186-193.
25. Polykarpou EM, Dalby PA, Papageorgiou LG. An MILP formulation for the synthesis of protein purification processes. Chem Eng Res Des. 2012;90:1262-1270.
26. Simaria AS, Turner R, Farid SS. A multi-level metaheuristic algorithm to optimise antibody purification processes at the bioprocess business interface. Biochem Eng J. 2012;69:144-154.
27. Allmendinger R, Simaria AS, Farid SS. Efficient discovery of chromatography equipment sizing strategies for antibody purification processes using evolutionary computing. Parallel Problem Solving Nature PPSN XII. 2012;7492:468-477.
28. Stonier A, Pain D, Westlake A, Hutchinson N, Thornhill N, Farid SS. Integration of stochastic simulation with multivariate analysis: short-term facility fit prediction. Biotechnol Prog. 2013;29:368-377.
29. Brooke A, Kendrick D, Meeraus A, Raman R. GAMS-A User's Guide. Washington, D.C.: GAMS Development Corporation; 2012.